Ozempic vs Wegovy

They share the same active ingredient — semaglutide — and work through identical GLP-1 receptor mechanisms. But they carry separate FDA approvals for different indications: Ozempic for type 2 diabetes and cardiovascular risk reduction, Wegovy specifically for chronic weight management. The maximum available strength also differs, with Wegovy reaching 2.4 mg versus Ozempic's 2 mg ceiling.

Ozempic is not FDA-approved for weight loss. Some clinicians prescribe it off-label in that context, but Wegovy is the FDA-approved semaglutide option for weight management and reaches a higher 2.4 mg maintenance strength. Insurance coverage for off-label use of Ozempic for weight loss is generally unavailable — check with your plan and prescriber.

Wegovy reaches a higher maximum available strength: 2.4 mg per week at maintenance, versus Ozempic's maximum of 2 mg. Both contain the same semaglutide molecule. The difference is in the approved dosing ceiling, not the underlying compound.

Both medications carry high list prices set by Novo Nordisk. Coverage depends heavily on your individual insurance plan. Ozempic is more commonly covered when prescribed for a type 2 diabetes diagnosis. Wegovy's coverage for obesity has historically been more variable — many plans have excluded obesity medications, though this is slowly changing. Patient assistance programs exist through Novo Nordisk for both drugs.

Only a prescribing clinician can determine whether switching is appropriate for your situation. Because both contain semaglutide, a provider familiar with your health history and current dosing can advise on whether a transition makes sense and, if so, how to approach it. Do not switch or adjust doses without clinical guidance.